US Stock MarketDetailed Quotes

Allogene Therapeutics (ALLO)

Watchlist
  • 2.720
  • -0.190-6.53%
Close Apr 10 15:59 ET
  • 3.090
  • +0.370+13.60%
Post 19:59 ET
663.08MMarket Cap-3.13P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Allogene Therapeutics (ALLO) Revenue Breakdown Overview

By Business/Source

Currency:USD
2024/FY
Stock NameRevenueRatio
Developing and commercializing genetically engineered allogeneic T cell product candidates for the22K100.00%

By Country/Region

Currency:USD
2024/FY
Stock NameRevenueRatio
United States22K100.00%
Market Insights
No. Symbol 20D % Chg
Sample Name
Sample Code
 +10.02%
Sample Name
Sample Code
 +5.43%
Sample Name
Sample Code
 +2.46%
4
SPDR S&P Oil & Gas Exploration & Production ETF
XOP
+1.46%
5
United Sts 12 Month Oil Fd Lp Unit Ben Int
USL
+0.70%
View More
China Concept Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +12.34%
Sample Name
Sample Code
 +11.49%
Sample Name
Sample Code
 +10.29%
4
Futu Holdings Ltd
FUTU
+10.23%
5
Hesai
HSAI
+9.84%
View More
Middle East conflict spreads to the stock market! How should investors respond?
On April 12 local time, U.S. Vice President Vance stated that negotiations between the United States and Iran failed to reach an agreement, Show More
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
Hormuz, Term Structure and USO: Navigating the Energy Storm

- No more -